Proxy Votes Now

Home › Activist investors › Doma Perpetual Capital Management LLC

Doma Perpetual Capital Management LLC

Dissident not on the roster. Positions and campaigns from Doma Perpetual Capital Management LLC’s SEC filings. Updated November 20, 2026.

Filer entities
Doma Perpetual Capital Management LLC
SEC CIK
1962221 (Doma Perpetual Capital Management LLC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
0current positions
0new or changed in 90 days
0active campaigns
1campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (0)

No current position by this definition.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (1)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Pacira BioSciences, Inc.Board seats Contested vote held — 0 of 3 of the activist's nominees elected Jun 9, 2026 Dec 11, 2024 Proxy contest filed latest (16) how managers voted

How large managers voted in Doma Perpetual Capital Management LLC’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

Contested director elections at which Doma Perpetual Capital Management LLC had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.

Top 20 managers across 1 contest

ManagerBacked the activistPacira BioScience…
2026
Vanguard0 of 1 (0%) Company
BlackRock0 of 1 (0%) Company
Fidelity0 of 1 (0%) Company
State Street0 of 1 (0%) Company
American Century1 of 1 (100%) Activist
IMPAX FUNDS SERIES TRUST I0 of 1 (0%) Company
Charles Schwab0 of 1 (0%) Company
Dimensional0 of 1 (0%) Company
DWS0 of 1 (0%) Company
World Funds Trust0 of 1 (0%) Company
EA Series Trust0 of 1 (0%) Company
Pacer Funds Trust0 of 1 (0%) Company
James Alpha Funds Trust1 of 1 (100%) Activist
Columbia Threadneedle0 of 1 (0%) Company
Hartford0 of 1 (0%) Company
SEI0 of 1 (0%) Company
Victory Capital0 of 1 (0%) Company
EXCHANGE TRADED CONCEPTS TRUST0 of 1 (0%) Company
Equitable0 of 1 (0%) Company
Principal Exchange-Traded Funds0 of 1 (0%) Company

— = no N-PX votes on the contested director elections found for that manager.

Pacira BioSciences, Inc. · meeting Jun 9, 2026 · 0 of 3 of the activist’s nominees elected

Result: Form 8-K, Item 5.07. Activist’s nominees: Oliver Benton Curtis III (not elected (8-k tally)); Eric de Armas (not elected (8-k tally)); Christopher Dennis (not elected (8-k tally)). Company’s nominees: Christopher J. Christie (elected (8-k tally)); Samit Hirawat (elected (8-k tally)); Thomas Wiggans (elected (8-k tally)).

ManagerStanceFOR the activist’s nomineesAvg. shares FOR each activist nomineeFOR the company’s nominees
Vanguard Backed the company's nominees 2 of 112 fund votes 0 136 of 164 fund votes
BlackRock Backed the company's nominees 1 of 54 fund votes 53,237 53 of 54 fund votes
Fidelity Backed the company's nominees 1 of 54 fund votes 9,285 53 of 54 fund votes
State Street Backed the company's nominees 0 of 33 fund votes 0 33 of 33 fund votes
American Century Backed the activist's nominees 24 of 27 fund votes 802,513 3 of 27 fund votes
IMPAX FUNDS SERIES TRUST I Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Charles Schwab Backed the company's nominees 0 of 24 fund votes 0 24 of 24 fund votes
Dimensional Backed the company's nominees 0 of 21 fund votes 0 14 of 21 fund votes
DWS Backed the company's nominees 0 of 6 fund votes 0 6 of 6 fund votes
World Funds Trust Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
EA Series Trust Backed the company's nominees 0 of 9 fund votes 0 5 of 9 fund votes
Pacer Funds Trust Backed the company's nominees 0 of 9 fund votes 0 9 of 9 fund votes
James Alpha Funds Trust Backed the activist's nominees 3 of 3 fund votes 138,400 0 of 3 fund votes
Columbia Threadneedle Backed the company's nominees 0 of 9 fund votes 0 9 of 9 fund votes
Hartford Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
SEI Backed the company's nominees 0 of 15 fund votes 0 15 of 15 fund votes
Victory Capital Backed the company's nominees 0 of 12 fund votes 0 12 of 12 fund votes
EXCHANGE TRADED CONCEPTS TRUST Backed the company's nominees 0 of 6 fund votes 0 6 of 6 fund votes
Equitable Backed the company's nominees 0 of 21 fund votes 0 21 of 21 fund votes
Principal Exchange-Traded Funds Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
TIAA Backed the company's nominees 0 of 12 fund votes 0 12 of 12 fund votes
Invesco Backed the company's nominees 0 of 24 fund votes 0 24 of 24 fund votes
ADVISORS' INNER CIRCLE FUND Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Jackson National Backed the company's nominees 0 of 9 fund votes 0 7 of 9 fund votes
QUANTITATIVE MASTER SERIES LLC Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Simplify Exchange Traded Funds Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Russell Investments Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Bridge Builder Trust Backed the company's nominees 0 of 9 fund votes 0 9 of 9 fund votes
Nationwide Backed the company's nominees 0 of 15 fund votes 0 15 of 15 fund votes
Goldman Sachs Backed the company's nominees 0 of 6 fund votes 0 6 of 6 fund votes
NYLIM VP FUNDS TRUST Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Northern Trust Backed the company's nominees 0 of 12 fund votes 0 8 of 12 fund votes
WisdomTree Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Lincoln Financial Backed the company's nominees 0 of 12 fund votes 0 10 of 12 fund votes
Prudential/PGIM Backed the company's nominees 0 of 6 fund votes 0 5 of 6 fund votes
JPMorgan Backed the activist's nominees 2 of 3 fund votes 24,779 1 of 3 fund votes
Principal Backed the company's nominees 0 of 9 fund votes 0 9 of 9 fund votes
Empower Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes
Voya Backed the company's nominees 0 of 9 fund votes 0 9 of 9 fund votes
Thrivent Backed the company's nominees 0 of 3 fund votes 0 3 of 3 fund votes

47 smaller managers not shown.

Source: N-PX reports filed by 87 managers for the meeting of Jun 9, 2026; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Contest vote: nominees not elected
Outcome of each campaign (1)
CompanyOutcomeDetailDateFirst filing
Pacira BioSciences, Inc. Contest vote: nominees not elected 0 of 3 of the activist's nominees elected Jun 9, 2026 Dec 11, 2024

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Doma Perpetual Capital Management LLC’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Pacira BioSciences, Inc. · Doma Perpetual Capital Management LLC first disclosed Dec 11, 2024 · 3 other filings
HolderFormDateStake
Millennium Management LLC Schedule 13G Jan 15, 2025 5.1%
BlackRock, Inc. Schedule 13G Apr 28, 2025 15.2%
Pacer US Small Cap Cash Cows ETF Schedule 13G May 2, 2025 6.9%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.